End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.9 CNY | +4.71% | +5.82% | -27.88% |
Apr. 30 | Pharmaron Beijing's Profit Rises 17% in 2023 | MT |
Apr. 29 | Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company returns high margins, thereby supporting business profitability.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.88% | 4.48B | B+ | ||
+23.37% | 46.71B | B- | ||
+48.83% | 41.8B | A | ||
-0.94% | 41.52B | B | ||
-5.86% | 29.55B | C | ||
+11.29% | 25.78B | B- | ||
-20.92% | 19.26B | B | ||
+3.20% | 12.14B | B+ | ||
-2.67% | 12.08B | C+ | ||
+30.23% | 11.98B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300759 Stock
- Ratings Pharmaron Beijing Co., Ltd.